NCCN 2018-2019 Oncology Case Manager and Medical Director Program: Management of Bone Health in Patients with Cancer

January 25, 2019

With the improved effectiveness of cancer treatment, more and more patients are surviving longer and may experience fractures as a long-term complication of bone loss. Much of the morbidity and mortality associated with bone loss and fractures is preventable with appropriate screening followed by lifestyle interventions. In the real world, not all cancer patients at risk for bone loss undergo screening. Effective screening and timely interventions are essential for reducing bone-related morbidity. Education on causative risk factors, mechanisms, and prevention and treatment strategies for cancer therapy-related bone loss in hematologic and specific solid malignancies is important. 

The management of long-term bone health for patients with cancer requires a broad knowledge and full understanding of the complementary benefits of available agents along with potential limitations. Although the risk/benefit ratio is usually markedly in favor of treatment, clinicians should be aware of potential adverse effects from these agents used in preventing bone loss, including patient populations deriving benefit, timing, scheduling of therapy, and specific clinical benefits.

Target Audience

This program is designed to meet the educational needs of case managers, nurses in other roles (e.g., quality management and utilization review), medical directors at managed care organizations, reinsurers, TPAs, and case management and disease management companies who interact with, counsel, and refer patients with cancer to appropriate sources of care and/or make coverage decisions. Programs may also be of interest to nurses, nurse navigators/care coordinators, and physicians who work directly with patients in clinical settings as well as clinical pharmacists in managed care organizations and other settings.

Learning Objectives

Following this activity, participants should be able to:

  • Effectively assess patients at risk for cancer-related skeletal complications and select appropriate management strategy.
  • Outline current indications, dosing and administration of currently available bone-targeted agents used in patients with cancer.
  • Describe the adverse effects and safety considerations of the bone-targeted agents.
Additional information
Supporters: 

This activity is supported by educational grants from:

  • Astellas
  • AstraZeneca
  • Celgene Corporation
  • Ethicon
  • Novartis Pharmaceuticals
  • Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Course summary
Available credit: 
  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 CCM clock hours
  • 1.25 Participation
Course opens: 
11/08/2018
Course expires: 
03/17/2019
Event starts: 
01/25/2019 - 2:15pm
Event ends: 
01/25/2019 - 3:30pm
Cost:
$0.00

Azeez Farooki, MD
Memorial Sloan Kettering Cancer Center

Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

Physicians
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NCCN designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.25 hours of Category 1 credit for completing this activity.

Nurses
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

NCCN designates this educational activity for a maximum of 1.25 contact hours.

Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. Credit approval for case managers is pending for this program.

Pharmacists

National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

NCCN designates this knowledge-based continuing education activity for 1.25 contact hours (0.125 CEUs) of continuing education credit. UAN: TBD

Available Credit

  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 CCM clock hours
  • 1.25 Participation

Accreditation Period

Course opens: 
11/08/2018
Course expires: 
03/17/2019

Price

Cost:
$0.00
Please login or register to take this course.

Click the Take Course button to register for this upcoming live webinar.

This webinar will be presented live one time only on Friday, January 25, 2019, from 2:15 - 3:30 PM Eastern Standard Time (EST) (UTC -5).  To convert the start time of this webinar for other time zones, click here.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing